Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aquestive Therapeutics, Inc.
< Previous
1
2
Next >
Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET
October 31, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Provides Business Update
October 09, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film
September 20, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date
September 11, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
August 23, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference
August 02, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film
July 27, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET
July 25, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
July 25, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit
July 06, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
June 29, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study
May 31, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 02, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
April 26, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
April 20, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
April 18, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
March 29, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
March 07, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 01, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
February 22, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 21, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
January 06, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
December 22, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
November 29, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
November 15, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
November 09, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 01, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
October 27, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
ASRT
Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims
October 24, 2022
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.